Phase 3Terminated
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer and Low Risk for Local Failure: A Randomized Phase III Trial of the German Rectal Cancer Study Group
- Sponsor
- Ralf Hofheinz (Academic or other)
- Enrolment
- 215 enrolled
- Conditions
- Rectal Cancer
- Interventions
- mFOLFOX (neoadjuvant); XELOX (neoadjuvant); mFOLFOX (adjuvant); XELOX (adjuvant); Capecitabine (adjuvant); infusional 5-FU/FA "AIO" regimen (adjuvant); infusional 5-FU/FA "de Gramont" (adjuvant)
- Ages
- adults, older adults
- Registry
- NCT04495088, EUCTR2018-001356-35
Full record on ClinicalTrials.gov
From the registry
This is a multicenter, prospective, randomized, stratified, controlled, open-label study comparing preoperative FOLFOX versus postoperative risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk for local failure
Primary outcomes
- disease-free survival
History
Last registry update
Primary completion
Started
Registered